Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Newbury Pharmaceuticals AB's EBIT per Share for the
three
months ended in Feb. 2026 was €-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 was €-0.08.
During the past 3 years, the average EBIT per Share Growth Rate was -2.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Newbury Pharmaceuticals AB's EBIT per Share or its related term are showing as below:
FRA:P52'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -18.5 Med: -10.4 Max: -2.3
Current: -2.3
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Newbury Pharmaceuticals AB was -2.30% per year. The lowest was -18.50% per year. And the median was -10.40% per year.
FRA:P52's 3-Year EBIT Growth Rate is ranked worse than 65.31% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs FRA:P52: -2.30
Newbury Pharmaceuticals AB (FRA:P52) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Newbury Pharmaceuticals AB EBIT per Share Related Terms
Newbury Pharmaceuticals AB EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB (FRA:P52) has a EBIT per Share of €-0.08 as of Feb. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Newbury Pharmaceuticals AB and its competitors. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #529 out of 810 companies in the Drug Manufacturers industry, placing it in the top 65.3%.
Is Newbury Pharmaceuticals AB's EBIT per Share too high?
Newbury Pharmaceuticals AB's current EBIT per Share is €-0.08. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #529 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #529 out of 810 companies for EBIT per Share. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current EBIT per Share is €-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current EBIT per Share of €-0.08. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current EBIT per Share is €-0.08. Newbury Pharmaceuticals AB's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current EBIT per Share is €-0.08 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.
Key valuation signals for FRA:P52:
EBIT per Share: €-0.08
GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
42GF Score
Get the complete analysis for FRA:P52
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P52 has been successfully added to your 
